Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,065 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.
Blasi M, Kazdal D, Thomas M, Christopoulos P, Kriegsmann M, Brandt R, Volckmar AL, Kirchner M, Heußel CP, Stenzinger A, Kuon J. Blasi M, et al. Among authors: thomas m. Case Rep Oncol. 2021 Mar 18;14(1):477-482. doi: 10.1159/000513904. eCollection 2021 Jan-Apr. Case Rep Oncol. 2021. PMID: 33976623 Free PMC article.
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.
Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H, Weichert W. Warth A, et al. Among authors: thomas m. J Clin Oncol. 2012 May 1;30(13):1438-46. doi: 10.1200/JCO.2011.37.2185. Epub 2012 Mar 5. J Clin Oncol. 2012. PMID: 22393100
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.
Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E, Goeppert B, Thomas M, Herth FJ, Dienemann H, Schnabel PA, Schirmacher P, Hoffmann H, Muley T, Weichert W. Warth A, et al. Among authors: thomas m. Eur Respir J. 2014 Mar;43(3):872-83. doi: 10.1183/09031936.00018013. Epub 2013 Aug 29. Eur Respir J. 2014. PMID: 23988776 Free article.
Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC).
Rieber J, Deeg A, Ullrich E, Foerster R, Bischof M, Warth A, Schnabel PA, Muley T, Kappes J, Heussel CP, Welzel T, Thomas M, Steins M, Dienemann H, Debus J, Hoffmann H, Rieken S. Rieber J, et al. Among authors: thomas m. Lung Cancer. 2016 Jan;91:41-7. doi: 10.1016/j.lungcan.2015.11.014. Epub 2015 Nov 25. Lung Cancer. 2016. PMID: 26711933
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Kim DW, et al. Among authors: thomas m. Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11. Lancet Oncol. 2016. PMID: 26973324 Free PMC article. Clinical Trial.
11,065 results
You have reached the last available page of results. Please see the User Guide for more information.